1
|
Telles VM, Rodriguez S, Torres M, Schneider J, Haughton J, Maldonado M, Arredondo E. Barriers and facilitators to implementing a multilevel, multicomponent intervention promoting colorectal cancer screening in health centers: a qualitative study of key informant perspectives. BMC Health Serv Res 2024; 24:404. [PMID: 38553723 PMCID: PMC10981354 DOI: 10.1186/s12913-024-10749-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 02/19/2024] [Indexed: 04/01/2024] Open
Abstract
BACKGROUND Colorectal cancer (CRC) continues to be a major cause of death in the U.S. despite the availability of effective screening tools. U.S. Latinos have lower rates of CRC screening and higher rates of death due to colorectal disease compared to non-Hispanic whites. Federally Qualified Health Centers (FQHCs) serve medically underserved populations, including many Latino patients. Given the low CRC screening rates, identifying culturally sensitive and cost-effective methods of promoting screening is a priority for many FQHCs. METHODS We interviewed FQHC leaders and providers using the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to implementation of a multilevel, multicomponent (ML-MC) CRC screening intervention (i.e., promotor navigation and group-based education) in FQHCs. A rapid qualitative analysis approach was used to identify themes organized according to the following CFIR constructs: intervention characteristics, outer and inner settings, and characteristics of the individual. RESULTS We completed interviews with 13 healthcare professionals in leadership positions at six FQHCs. The participating FQHCs perceived the ML-MC screening CRC program as feasible and expressed interest in implementing the program at their sites. Facilitators included financial incentives for increasing screening rates, the need for patient education programming, and involving promotores to support the work of clinical teams. Barriers included concerns about available resources to implement new programs, lack of federal reimbursement for health education, competing priorities of other health concerns, and the need for more resources for confirmatory screening and treatment following a positive screen. CONCLUSIONS FQHCs provide essential primary care to millions of underserved patients in the U.S. and have the ability and motivation to provide screenings for colorectal cancer. Partnering with an academic institution to deliver a group-based, promotor-led CRC screening intervention for patients not up to date with screening could help increase screening rates. By identifying the specific barriers and facilitators to implementing CRC intervention, findings suggest that group-based, promotor-led interventions are a promising approach.
Collapse
Affiliation(s)
- V M Telles
- Joint Doctoral Program in Public Health at San Diego State University, University of California, San Diego, USA.
| | - S Rodriguez
- Department of Anthropology, University of California, Riverside, Riverside, USA
| | - M Torres
- Joint Doctoral Program in Public Health at San Diego State University, University of California, San Diego, USA
| | - J Schneider
- School of Public Health, San Diego State University Research Foundation, San Diego, USA
| | - J Haughton
- Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, USA
| | - M Maldonado
- School of Public Health, San Diego State University Research Foundation, San Diego, USA
| | - E Arredondo
- School of Public Health, San Diego State University Research Foundation, San Diego, USA
- Psychology Department, San Diego State University, San Diego, USA
| |
Collapse
|
2
|
Maldonado M, Fan Z, Abe KM, Letts JA. Author Correction: Plant-specific features of respiratory supercomplex I + III 2 from Vigna radiata. Nat Plants 2023; 9:501. [PMID: 36805039 PMCID: PMC10027607 DOI: 10.1038/s41477-023-01373-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Affiliation(s)
- M Maldonado
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA.
- Department of Plant Biology, University of California, Davis, CA, USA.
| | - Z Fan
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA
| | - K M Abe
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA
| | - J A Letts
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA.
| |
Collapse
|
3
|
Maldonado M, Fan Z, Abe KM, Letts JA. Plant-specific features of respiratory supercomplex I + III 2 from Vigna radiata. Nat Plants 2023; 9:157-168. [PMID: 36581760 PMCID: PMC9873571 DOI: 10.1038/s41477-022-01306-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Accepted: 11/08/2022] [Indexed: 05/07/2023]
Abstract
The last steps of cellular respiration-an essential metabolic process in plants-are carried out by mitochondrial oxidative phosphorylation. This process involves a chain of multi-subunit membrane protein complexes (complexes I-V) that form higher-order assemblies called supercomplexes. Although supercomplexes are the most physiologically relevant form of the oxidative phosphorylation complexes, their functions and structures remain mostly unknown. Here we present the cryogenic electron microscopy structure of the supercomplex I + III2 from Vigna radiata (mung bean). The structure contains the full subunit complement of complex I, including a newly assigned, plant-specific subunit. It also shows differences in the mitochondrial processing peptidase domain of complex III2 relative to a previously determined supercomplex with complex IV. The supercomplex interface, while reminiscent of that in other organisms, is plant specific, with a major interface involving complex III2's mitochondrial processing peptidase domain and no participation of complex I's bridge domain. The complex I structure suggests that the bridge domain sets the angle between the enzyme's two arms, limiting large-scale conformational changes. Moreover, complex I's catalytic loops and its response in active-to-deactive assays suggest that, in V. radiata, the resting complex adopts a non-canonical state and can sample deactive- or open-like conformations even in the presence of substrate. This study widens our understanding of the possible conformations and behaviour of complex I and supercomplex I + III2. Further studies of complex I and its supercomplexes in diverse organisms are needed to determine the universal and clade-specific mechanisms of respiration.
Collapse
Affiliation(s)
- M Maldonado
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA.
- Department of Plant Biology, University of California, Davis, CA, USA.
| | - Z Fan
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA
| | - K M Abe
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA
| | - J A Letts
- Department of Molecular and Cellular Biology, University of California, Davis, CA, USA.
| |
Collapse
|
4
|
Maldonado M, Villamin CE, Murphy LE, Dasgupta A, Bassett RL, Correa Medina M, Bates TS, Martinez F, Knopfelmacher Couchonal AM, Klein K, Kelley JM. Oncology Patients Who Develop Transfusion-Associated Circulatory Overload: An Observational Study. Lab Med 2022; 53:344-348. [PMID: 35285900 PMCID: PMC9251653 DOI: 10.1093/labmed/lmab119] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Transfusion-associated circulatory overload (TACO) is a largely preventable transfusion complication that results in significant morbidity and mortality. Cancers, related treatments, and comorbidities are among the factors that can predispose patients to TACO, but currently there are limited data on this topic in the literature. METHODS We collected data retrospectively from the electronic health records of 93 adult patients with cancer who met Centers for Disease Control and Prevention (CDC) criteria for TACO from July 1, 2019, through October 31, 2020. The parameters we studied included demographics, comorbidities, treatment modalities, transfusion practices, and outcomes. We summarized data by means and ranges for continuous variables, and proportions for categorical variables. RESULTS During the study period, the incidence of TACO among oncology patients was 0.84 per 1000 transfusions (95% CI, 0.68-1.02), representing 6.6% of all reactions. This percentage is high, compared with 1%-6% among other populations. Unique characteristics such as hematology malignancy (75.3%), receipt of cardiotoxic chemotherapy (87.1%), pneumonia (57.0%), preexisting oxygen use (59.1%), dyspnea (62.4%), hypertension (55.9%), renal insufficiency (46.2%), daily use of corticosteroids (43.0%), daily use of diuretics (40.9%), daily use of beta-blockers (36.6%), and elevated NT-proBNP (33.3%) were frequently observed in these group of oncology patients. CONCLUSIONS Our study indicates that oncology patients have unique factors that may lead to diagnosis of TACO. Developing appropriate guidelines that apply to oncology patients, in addition to those set forth by the CDC, should be considered. Implementation by ordering healthcare providers of a tools that can predict TACO can help in early recognition and mitigation of TACO.
Collapse
Affiliation(s)
- Marisol Maldonado
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Colleen E Villamin
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Leah E Murphy
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Amitava Dasgupta
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Roland L Bassett
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Mayrin Correa Medina
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Tonita S Bates
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Fernando Martinez
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Adriana M Knopfelmacher Couchonal
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Kimberly Klein
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - James M Kelley
- Hemovigilance Unit, Department of Laboratory Medicine, Division of Pathology and Laboratory Medicine; The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
5
|
Cherney DZI, Segar M, Pandey A, Cannon CP, Cosentino F, Dagogo-Jack S, Pratley RE, Frederich R, Cater NB, Maldonado M, Liu J, Liu CC, Pong A, McGuire DK. Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been shown to slow the decline of kidney function in outcome trials, but the biological mediator(s) underlying the therapeutic benefit are not well established.
Purpose
We performed a post-hoc analysis exploring potential mediators of the effects of the SGLT2 inhibitor ertugliflozin on the VERTIS CV exploratory kidney composite outcome (sustained 40% decrease from baseline in estimated glomerular filtration rate [eGFR], chronic kidney replacement therapy or kidney death).
Methods
In VERTIS CV, 8246 participants with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease were randomised to placebo, ertugliflozin 5 mg or 15 mg (pooled for analyses, as prospectively planned), and were followed for a mean of 3.5 years. The hazard ratio (HR; 95% confidence interval) for the pre-specified exploratory kidney composite outcome was 0.66 (0.50, 0.88). Cox regression models were used to evaluate covariates that were significantly differentially changed from baseline with ertugliflozin treatment as candidate mediators, with a mediator identified as a covariate when added to an unadjusted model of randomised treatment assignment a) yielded a larger hazard ratio; and b) the mediator retained P<0.05 in the model (eGFR was excluded as a covariate). The percentage of mediation was determined by the proportional increase in the HR between the unadjusted and adjusted models for each post-randomisation period: early (first change from baseline measurement) and average (weighted average of change from baseline from all post-baseline measurements). Each potential mediator was tested individually, so across analyses, mediation % sums to >100%.
Results
Of 22 covariates significantly changed by ertugliflozin, nine were identified as potential mediators (Table). The covariates with a high percentage of mediation were those related to changes in blood erythrocytes (haemoglobin, haematocrit and red blood cell mass), with average changes in haemoglobin having the highest percentage of mediation (61.8%). Serum uric acid was associated with a mediation of 29.4% and 50.0% for the early and average post-randomisation effect periods, respectively. Early changes in glycated haemoglobin had a large mediation (50%), but the average change during the trial was not significant. Average change in serum albumin had a large mediation (29.4%). Average changes in body weight and systolic blood pressure had percentages of mediation of 41.2% and 14.7%, respectively.
Conclusion
Multiple factors may be involved in the reduction of the kidney composite outcome observed with ertugliflozin. In the short-term, changes in glycaemia had a high mediation effect. Over the long-term, changes suggestive of haemoconcentration and/or haematopoiesis (natriuresis-related effects), showed the highest percentage of mediation, followed by changes in serum uric acid and body weight (glucosuria-related effects).
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA in collaboration with Pfizer Inc., New York, NY, USA
Collapse
Affiliation(s)
- D Z I Cherney
- University of Toronto, Division of Nephrology, Toronto, Canada
| | - M Segar
- University of Texas Southwestern Medical Center, Dallas, United States of America
| | - A Pandey
- University of Texas Southwestern Medical Center, Dallas, United States of America
| | - C P Cannon
- Brigham and Women's Hospital, Harvard Medical School, Cardiovascular Divison, Boston, United States of America
| | - F Cosentino
- Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden
| | - S Dagogo-Jack
- University of Tennessee Health Science Center, Memphis, United States of America
| | - R E Pratley
- AdventHealth Translational Research Institute, Memphis, United States of America
| | - R Frederich
- Pfizer Inc., Collegeville, United States of America
| | - N B Cater
- Pfizer Inc., New York, United States of America
| | - M Maldonado
- Merck Sharp & Dohme Limited, London, United Kingdom
| | - J Liu
- Merck & Co., Inc., Kenilworth, New Jersey, United States of America
| | - C.-C Liu
- Merck & Co., Inc., Kenilworth, New Jersey, United States of America
| | - A Pong
- Merck & Co., Inc., Kenilworth, New Jersey, United States of America
| | - D K McGuire
- University of Texas Southwestern Medical Center; Parkland Hospital and Health System, Dallas, United States of America
| |
Collapse
|
6
|
Segar MW, Pandey A, Cherney DZI, Cannon CP, Cosentino F, Dagogo-Jack S, Pratley RE, Shih WJ, Frederich R, Cater NB, Maldonado M, Liu J, Liu C, Pong A, McGuire DK. Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce risk of hospitalisation for heart failure (HHF) in outcome trials, but the biological mediators underlying the therapeutic benefit are not well established.
Purpose
To identify potential biological mediators through which ertugliflozin reduces risk of HHF.
Methods
In VERTIS CV, 8246 patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomised to ertugliflozin 5 or 15 mg (observations pooled as prospectively planned) or placebo. Cox regression models were used to evaluate the associations between changes in 26 potential mediators with outcomes. Potential mediators were selected based on proposed mechanisms and/or differential change from baseline with SGLT2 inhibitors. Mediation criteria required 1) significant (P<0.05 for change from baseline) effects of ertugliflozin vs placebo on each potential mediator; and 2) significant (P<0.05) association of change in post-randomisation levels of the potential mediator with risk of HHF when added to an unadjusted model of randomised treatment assignment. Percent mediation was determined by comparing the unadjusted hazard ratio and hazard ratio adjusted for change in the potential mediator of interest. Each covariate was tested individually, such that percent mediation across the analyses summed to >100%. Time-dependent models were used to evaluate associations between early (change from baseline for the first post-baseline measurement) and average (weighted average of change from baseline using all post-baseline measurements) changes in covariates with clinical outcomes.
Results
Over a mean of 3.5 years, the incidence rate of HHF was 0.7 and 1.1 per 100 patient-years with ertugliflozin and placebo, respectively. Among 26 candidate mediators, 9 and 13 met the mediation criteria based on early and average changes, respectively. The 3 covariates with the largest mediating effects of early changes included haematocrit (40%), haemoglobin (27%) and HDL-C (23%) (Table); other significant biomarkers included urine albumin/creatinine ratio, and serum albumin, uric acid, chloride, protein and sodium. The 3 biomarkers with the largest mediating effects in average changes included haemoglobin (63%), albumin (50%) and uric acid (47%) (Table); other significant biomarkers included haematocrit, urine albumin/creatinine ratio, body weight, serum protein and chloride, systolic blood pressure, ALT, BUN, eGFR and heart rate.
Conclusions
In these analyses from the VERTIS CV trial, potential markers of volume status and haemoconcentration and/or haematopoiesis were the strongest mediators of the effect of ertugliflozin on reducing risk of HHF in the early and average change periods. Other potential mediators included uric acid, lipid markers and kidney parameters. These findings provide insights into potential mechanisms through which ertugliflozin, and potentially the SGLT2 inhibitor class, may prevent HHF.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.
Collapse
Affiliation(s)
- M W Segar
- University of Texas Southwestern Medical Center, Dallas, United States of America
| | - A Pandey
- University of Texas Southwestern Medical Center, Dallas, United States of America
| | | | - C P Cannon
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America
| | - F Cosentino
- Unit of Cardiology, Karolinska Institute & Karolinska University Hospital, Stockholm, Sweden
| | - S Dagogo-Jack
- University of Tennessee Health Science Center, Memphis, United States of America
| | - R E Pratley
- AdventHealth Translational Research Institute, Orlando, United States of America
| | - W J Shih
- Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, Piscataway, United States of America
| | - R Frederich
- Pfizer Inc., Collegeville, United States of America
| | - N B Cater
- Pfizer Inc., New York, United States of America
| | | | - J Liu
- Merck & Co., Inc., Kenilworth, United States of America
| | - C Liu
- Merck & Co., Inc., Kenilworth, United States of America
| | - A Pong
- Merck & Co., Inc., Kenilworth, United States of America
| | - D K McGuire
- University of Texas Southwestern Medical Center & Parkland Health and Hospital System, Dallas, United States of America
| |
Collapse
|
7
|
Cosentino F, Cannon CP, Cherney DZI, Dagogo-Jack S, Pratley RE, Charbonnel B, Shih WJ, Mancuso JP, Maldonado M, Frederich R, Cater NB, Wang S, McGuire DK. Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2650] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
We analysed data from the VERTIS CV trial that investigated the CV and kidney safety and efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (ERTU) vs placebo (PBO) to assess the impact of metformin (MET) use at baseline (BL). These analyses are timely because the recent ESC guidelines recommendation to use SGLT2 inhibitor or GLP-1 RAs as initial glucose-lowering therapy in patients with type 2 diabetes (T2D) with or at high risk for atherosclerotic cardiovascular disease (ASCVD) has been questioned because outcome trials of these drug classes included a large proportion of patients with MET as background therapy, yet MET was not used at BL in approximately 25% of patients in each trial.
Purpose
These analyses determined cardiorenal endpoints of VERTIS CV according to use of BL MET to assess for evidence of treatment effect modification for ERTU by BL MET use, adjusting for the probability (propensity) of BL MET use.
Methods
VERTIS CV was an international, double-blind, PBO-controlled trial of 2 doses of ERTU (5 mg; 15 mg) vs PBO in patients with T2DM and ASCVD. As prospectively planned, the 2 ERTU dose groups were combined for all analyses vs PBO. Differences in risk of CV and kidney outcomes between ERTU and PBO across subgroups by BL MET use were conducted using Cox proportional hazards model along with propensity adjustment using inverse probability for treatment weighting to account for differences in patient mix between those with and without BL MET influenced by individual BL characteristics and risk factors. Treatment (categorical), BL MET use (categorical) and the interaction term between treatment and BL MET use subgroup (no or yes) were used in each model to assess effect modification by BL MET use. Hazard ratio and 95% CI are presented along with Pinteraction for evaluation of treatment effect modification by BL MET use.
Results
In VERTIS CV, 8246 patients were randomised to ERTU 5 mg, 15 mg or PBO. Of these, 6286 (76%) patients used MET (alone or with other glucose-lowering agents [GLA]) at BL. Differences in BL characteristics by BL MET use subgroup (no or yes) included a higher mean UACR (204.4 vs 129.8 mg/g), more patients with eGFR <60 mL/min/1.73 m2 (34.8% vs 17.9%), more patients on a single GLA (76.9% vs 18.3%), higher insulin use (67.6% vs 40.9%), lower sulphonylurea use (32.2% vs 43.8%) and a slightly longer disease duration (14.4 vs 12.5 years) in the subgroup without vs with BL MET, respectively. No significant differences in the relative risk for cardiorenal outcomes were observed with or without BL MET use (Figure; all Pinteraction values >0.05).
Conclusions
In VERTIS CV, there was no evidence for effect modification by BL MET use on the effects of ERTU on cardiorenal outcomes in patients with T2D and ASCVD.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.
Collapse
Affiliation(s)
- F Cosentino
- Unit of Cardiology, Karolinska Institute & Karolinska University Hospital, Stockholm, Sweden
| | - C P Cannon
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America
| | | | - S Dagogo-Jack
- University of Tennessee Health Science Center, Memphis, United States of America
| | - R E Pratley
- AdventHealth Translational Research Institute, Orlando, United States of America
| | | | - W J Shih
- Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, Piscataway, United States of America
| | - J P Mancuso
- Pfizer Inc., Groton, United States of America
| | | | - R Frederich
- Pfizer Inc., Collegeville, United States of America
| | - N B Cater
- Pfizer Inc., New York, United States of America
| | - S Wang
- Pfizer Inc., Groton, United States of America
| | - D K McGuire
- University of Texas Southwestern Medical Center & Parkland Health and Hospital System, Dallas, United States of America
| |
Collapse
|
8
|
Cherney D, Charbonnel B, Cosentino F, Pratley R, Dagogo-Jack S, Shih W, McGuire D, Frederich R, Maldonado M, Liu J, Pong A, Liu C, Cannon C. POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV. Kidney Int Rep 2021. [DOI: 10.1016/j.ekir.2021.03.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
9
|
Maldonado M, López-Acosta M, Beazley L, Kenchington E, Koutsouveli V, Riesgo A. Cooperation between passive and active silicon transporters clarifies the ecophysiology and evolution of biosilicification in sponges. Sci Adv 2020; 6:eaba9322. [PMID: 32832609 PMCID: PMC7439455 DOI: 10.1126/sciadv.aba9322] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 05/22/2020] [Indexed: 06/11/2023]
Abstract
The biological utilization of dissolved silicon (DSi) influences ocean ecology and biogeochemistry. In the deep sea, hexactinellid sponges are major DSi consumers that remain poorly understood. Their DSi consumption departs from the Michaelis-Menten kinetics of shallow-water demosponges and appears particularly maladapted to incorporating DSi from the modest concentrations typical of the modern ocean. Why did sponges not adapt to the shrinking DSi availability that followed diatom expansion some 100 to 65 million years ago? We propose that sponges incorporate DSi combining passive (aquaglyceroporins) and active (ArsB) transporters, while only active transporters (SITs) operate in diatoms and choanoflagellates. Evolution of greater silicon transport efficiency appears constrained by the additional role of aquaglyceroporins in transporting essential metalloids other than silicon. We discuss the possibility that lower energy costs may have driven replacement of ancestral SITs by less efficient aquaglyceroporins, and discuss the functional implications of conservation of aquaglyceroporin-mediated DSi utilization in vertebrates.
Collapse
Affiliation(s)
- M. Maldonado
- Department of Marine Ecology, Center for Advanced Studies of Blanes (CEAB-CSIC), Acceso Cala St. Francesc 14, Blanes 17300, Girona, Spain
| | - M. López-Acosta
- Department of Marine Ecology, Center for Advanced Studies of Blanes (CEAB-CSIC), Acceso Cala St. Francesc 14, Blanes 17300, Girona, Spain
| | - L. Beazley
- Department of Fisheries and Oceans, Bedford Institute of Oceanography, 1 Challenger Dr., Dartmouth, NS, Canada
| | - E. Kenchington
- Department of Fisheries and Oceans, Bedford Institute of Oceanography, 1 Challenger Dr., Dartmouth, NS, Canada
| | - V. Koutsouveli
- Department of Life Sciences, The Natural History Museum of London, Cromwell Road, SW7 5BD London, UK
| | - A. Riesgo
- Department of Life Sciences, The Natural History Museum of London, Cromwell Road, SW7 5BD London, UK
| |
Collapse
|
10
|
Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber DE, Caso C, Coppola G, Dickerson B, Dickinson S, Domoto-Reilly K, Faber K, Ferrall J, Fields J, Fishman A, Fong J, Foroud T, Forsberg LK, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY, Huey E, Irwin D, Jones D, Kantarci K, Karydas A, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Kraft R, Kremers WK, Kukull W, Litvan I, Ljubenkov P, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis S, McKinley E, Mendez MF, Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Roberson ED, Rogalski E, Sengdy P, Shaw L, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski J, Weintraub S, Wong B, Wszolek Z, Boeve BF, Rosen HJ, Boxer AL. Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. Alzheimers Dement 2020; 16:60-70. [PMID: 31914226 PMCID: PMC7192555 DOI: 10.1002/alz.12046] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Behavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding of the generalizability of assessments and treatments. METHODS A total of 135 sporadic (s-bvFTD; mean age 63.3 years; 34% female) and 99 familial (f-bvFTD; mean age 59.9; 48% female) bvFTD participants were identified. f-bvFTD cases included 43 with known or presumed chromosome 9 open reading frame 72 (C9orf72) gene expansions, 28 with known or presumed microtubule-associated protein tau (MAPT) mutations, 14 with known progranulin (GRN) mutations, and 14 with a strong family history of FTD but no identified mutation. RESULTS Participants with f-bvFTD were younger and had earlier age at onset. s-bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI-Q) scores due to more frequent endorsement of depression and irritability. DISCUSSION f-bvFTD and s-bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other.
Collapse
Affiliation(s)
- Hilary W Heuer
- University of California, San Francisco, San Francisco, California
| | - P Wang
- University of California, San Francisco, San Francisco, California
| | - K Rascovsky
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - A Wolf
- University of California, San Francisco, San Francisco, California
| | - B Appleby
- Case Western Reserve University, Cleveland, Ohio
| | - J Bove
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - Y Bordelon
- University of California, Los Angeles, Los Angeles, California
| | - P Brannelly
- Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas
| | | | - C Caso
- U Washington, Seattle, Washington
| | - G Coppola
- University of California, Los Angeles, Los Angeles, California
| | - B Dickerson
- Harvard University/MGH, Boston, Massachusetts
| | - S Dickinson
- Association for Frontotemporal Degeneration, Radnor, Pennsylvania
| | | | - K Faber
- National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana
| | - J Ferrall
- University of North Carolina, Chapel Hill, North Carolina
| | - J Fields
- Mayo Clinic, Rochester, Minnesota
| | - A Fishman
- Johns Hopkins University, Baltimore, Maryland
| | - J Fong
- University of California, San Francisco, San Francisco, California
| | - T Foroud
- National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana
| | | | | | | | - N Ghoshal
- Washington University, St. Louis, Missouri
| | - J Goldman
- Columbia University, New York, New York
| | | | | | - I Grant
- Northwestern University, Chicago, Illinois
| | - M Grossman
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - D Haley
- Mayo Clinic, Jacksonville, Florida
| | - G-Y Hsiung
- University of British Columbia, Vancouver, British Columbia, Canada
| | - E Huey
- Columbia University, New York, New York
| | - D Irwin
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - D Jones
- Mayo Clinic, Rochester, Minnesota
| | | | - A Karydas
- University of California, San Francisco, San Francisco, California
| | - D Kaufer
- University of North Carolina, Chapel Hill, North Carolina
| | - D Kerwin
- The University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas
| | | | - J Kornak
- University of California, San Francisco, San Francisco, California
| | - J H Kramer
- University of California, San Francisco, San Francisco, California
| | - R Kraft
- Mayo Clinic, Rochester, Minnesota
| | | | - W Kukull
- National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, Washington
| | - I Litvan
- University of California, San Diego, San Diego, California
| | - P Ljubenkov
- University of California, San Francisco, San Francisco, California
| | - I R Mackenzie
- University of British Columbia, Vancouver, British Columbia, Canada
| | - M Maldonado
- University of California, Los Angeles, Los Angeles, California
| | | | - S McGinnis
- Harvard University/MGH, Boston, Massachusetts
| | - E McKinley
- University of Alabama at Birmingham, Birmingham, Alabama
| | - M F Mendez
- University of California, Los Angeles, Los Angeles, California
| | - B L Miller
- University of California, San Francisco, San Francisco, California
| | - C Onyike
- Johns Hopkins University, Baltimore, Maryland
| | - A Pantelyat
- Johns Hopkins University, Baltimore, Maryland
| | - R Pearlman
- Bluefield Project, San Francisco, California
| | | | - M Potter
- National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana
| | | | - E M Ramos
- University of California, Los Angeles, Los Angeles, California
| | - K P Rankin
- University of California, San Francisco, San Francisco, California
| | - E D Roberson
- University of Alabama at Birmingham, Birmingham, Alabama
| | - E Rogalski
- Northwestern University, Chicago, Illinois
| | - P Sengdy
- University of British Columbia, Vancouver, British Columbia, Canada
| | - L Shaw
- University of Pennsylvania, Philadelphia, Pennsylvania
| | | | | | - N Tatton
- Association for Frontotemporal Degeneration, Radnor, Pennsylvania
| | - J Taylor
- University of California, San Francisco, San Francisco, California
| | - A Toga
- Laboratory of Neuroimaging (LONI), USC, Los Angeles, California
| | | | | | - B Wong
- Harvard University/MGH, Boston, Massachusetts
| | | | | | - H J Rosen
- University of California, San Francisco, San Francisco, California
| | - A L Boxer
- University of California, San Francisco, San Francisco, California
| |
Collapse
|
11
|
Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X, Furst DE, Ranganath VK, Maldonado M, Lee T, Reddy ST. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Atherosclerosis 2018; 275:107-114. [PMID: 29886354 DOI: 10.1016/j.atherosclerosis.2018.04.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2017] [Revised: 03/16/2018] [Accepted: 04/05/2018] [Indexed: 12/18/2022]
Abstract
BACKGROUND AND AIMS To evaluate changes in the high-density lipoprotein (HDL) proteome and HDL function in active rheumatoid arthritis (RA) patients initiating therapy with abatacept or adalimumab in the Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE) study. METHODS Ultra high-pressure liquid chromatography (UHPLC) coupled with ion mobility mass spectrometry (LC-IM-MS) was used to analyze proteins associated with immunoaffinity-captured HDL from plasma of 30 patients with RA randomized to either abatacept (n = 15) or adalimumab (n = 15) therapy. Paraoxonase 1 (PON1) activity, HDL anti-oxidant capacity, cholesterol profiles, and homocysteine levels were also measured at baseline and following treatment. Repeated-measures analyses were performed using mixed-effect linear models to model the within-subject covariance over time. RESULTS In models controlling for age, sex and treatment group, improvement in inflammation measured by decreases in CRP was associated with improvement in HDL function and changes in several HDL-associated proteins including significant decreases in lipopolysaccharide-binding protein, serum amyloid A-I (SAA-I) and inter-alpha-trypsin inhibitor heavy chain H4 (p values < 0.05). Improvement in disease activity was also associated with changes in multiple HDL-associated proteins. Adalimumab was associated with higher PON1 activity, HDL-associated serotransferrin, and HDL-associated immunoglobulin J chain, and lower HDL-associated SAA-I over time compared with abatacept. CONCLUSIONS Improvement in inflammation associated with treatment of RA, using either abatacept or adalimumab in the AMPLE study, was associated with improvement in HDL function and significant alterations in the HDL proteome, including proteins involved in the immune response, proteinase inhibition, and lipid metabolism.
Collapse
Affiliation(s)
| | - G B Gugiu
- Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - H Ge
- Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - A Shahbazian
- University of California Los Angeles, Los Angeles, CA, USA
| | - Y Y Lee
- University of California Los Angeles, Los Angeles, CA, USA
| | - X Wang
- University of California Los Angeles, Los Angeles, CA, USA
| | - D E Furst
- University of California Los Angeles, Los Angeles, CA, USA
| | - V K Ranganath
- University of California Los Angeles, Los Angeles, CA, USA
| | | | - Terry Lee
- Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - S T Reddy
- University of California Los Angeles, Los Angeles, CA, USA
| |
Collapse
|
12
|
Meneguz Moreno R, Costa Jr J, Gomes N, Ramos A, Meneghelo Z, Maldonado M, Ferreira Neto A, Franca J, Siqueira D, Esteves C, Braga S, Sousa A, Sousa J, Abizaid A. P2999Predictors of immediate results and very long-term follow-up after percutaneous mitral balloon valvuloplasty in rheumatic mitral stenosis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p2999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Valencia F, Muro J, Solórzano R, Maldonado M, Flores C, Quintana S. Response of diffuse large B-cell lymphoma treated with R-CHOP and prognostic factors associated: A single institution analysis in Lima, Peru. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_79] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Valencia
- Oncología Médica; Instituto Nacional de Enfermedades Neoplásicas; Lima Peru
| | - J. Muro
- Oncología Médica; Instituto Nacional de Enfermedades Neoplásicas; Lima Peru
| | - R. Solórzano
- Oncología Médica; Instituto Nacional de Enfermedades Neoplásicas; Lima Peru
| | - M. Maldonado
- Oncología Médica; Instituto Nacional de Enfermedades Neoplásicas; Lima Peru
| | - C. Flores
- Dirección Científica y Académica, OncoSalud; Lima Peru
| | - S. Quintana
- Oncología Médica; Instituto Nacional de Enfermedades Neoplásicas; Lima Peru
| |
Collapse
|
14
|
Maldonado M, Desbiens A, Poulin É, del Villar R, Riquelme A. Automatic control of bubble size in a laboratory flotation column. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.minpro.2015.06.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Charles-Schoeman C, Gugiu G, Ge H, Shahbazian A, Lee Y, Wang X, Furst D, Ranganath V, Maldonado M, Reddy S. FRI0065 Proteomic Profiling Following Immunoaffinity Capture of High-Density Lipoprotein (HDL) Identifies Changes in Multiple HDL-Associated Proteins Following Treatment with Abatacept or Adalimumab in the Ample Study of Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
16
|
Quintero M, Núñez M, Mellado S, Maldonado M, Wehinger S. Evaluation of store lesion in platelet obtained by apheresis compared to platelet derived from whole blood and its impact on the in vitro functionality. Transfus Apher Sci 2015; 53:293-9. [PMID: 26043812 DOI: 10.1016/j.transci.2015.05.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Revised: 04/30/2015] [Accepted: 05/20/2015] [Indexed: 01/26/2023]
Abstract
Platelet units for transfusion purposes are obtained manually from whole blood or by apheresis, in an automated process. In both methods, platelets during storage present a characteristics grouped under the name "storage lesion" that are associated with adverse effects on platelet units. Oxidative stress has been claimed to be one of major causes, leading to activation and apoptosis processes affecting their post transfusion functionality. In this work, we observed an association between apheresis and a reduced presence of oxidative stress and better results in functional markers in stored platelets, compared to manually obtained platelets. Then, apheresis which would ensure a greater number of functional platelets during the 5 days of storage, compared to concentrates obtained from whole blood.
Collapse
Affiliation(s)
- M Quintero
- Blood Bank and Transfusion Service, Foundation Valle of Lili Clinic, Cali, Colombia; Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Talca, Chile
| | - M Núñez
- Blood Bank, Santa María Clinic, Santiago de Chile, Chile
| | - S Mellado
- Blood Bank, Santa María Clinic, Santiago de Chile, Chile
| | - M Maldonado
- Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Talca, Chile
| | - S Wehinger
- Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Talca, Chile.
| |
Collapse
|
17
|
Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BMK. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study. Pituitary 2014; 17:320-6. [PMID: 23943009 PMCID: PMC4085509 DOI: 10.1007/s11102-013-0503-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In a previous 15-day, Phase II study of patients with de novo or persistent/recurrent Cushing's disease (core study), treatment with pasireotide 600 μg sc bid reduced urinary free cortisol (UFC) levels in 76% of patients and normalized UFC in 17%. The objective of this study was to evaluate the efficacy and safety of extended treatment with pasireotide. This was a planned, open-ended, single-arm, multicenter extension study (primary endpoint: 6 months). Patients aged ≥18 years with Cushing's disease who completed the core study could enter the extension if they achieved UFC normalization at core study end and/or obtained significant clinical benefit. Of the 38 patients who completed the core study, 19 entered the extension and 18 were included in the efficacy analyses (three responders, 11 reducers, four non-reducers in the core study). At data cut-off, median treatment duration in the extension was 9.7 months (range: 2 months to 4.8 years). At extension month 6, 56% of the 18 patients had lower UFC than at core baseline and 22% had normalized UFC. Of the four patients who remained on study drug at month 24, one had normalized UFC. Reductions in serum cortisol, plasma adrenocorticotropic hormone, body weight and diastolic blood pressure were observed. The most common adverse events were mild-to-moderate gastrointestinal disorders and hyperglycemia. Pasireotide offers a tumor-directed medical therapy that may be effective for the extended treatment of some patients with Cushing's disease.
Collapse
Affiliation(s)
- M Boscaro
- Division of Endocrinology, Polytechnic University of Marche, 60126, Ancona, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Connolly S, Maldonado M, Schiff M, Weinblatt M, Fleischmann R, Robinson W, Sokolove J. FRI0039 Modulation of the ACPA Fine Specificity in Patients with RA Treated with Either Abatacept or Adalimumab in the AMPLE Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2469] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
19
|
Fleischmann R, Weinblatt M, Schiff M, Khanna D, Maldonado M, Nadkarni A, Fay J, Furst D. SAT0246 Correlation of Clinical Response with Patient-Reported Outcomes in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: 2-Year Results: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
20
|
Fleischmann R, Schiff M, Weinblatt M, Maldonado M, Massarotti E, Fay J, Yazici Y. FRI0033 Association of Radiographic Outcomes with Low Disease Activity and Remission and Sustainability of Response with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the AMPLE Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2959] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BMK. High variability in baseline urinary free cortisol values in patients with Cushing's disease. Clin Endocrinol (Oxf) 2014; 80:261-9. [PMID: 23746264 PMCID: PMC4231220 DOI: 10.1111/cen.12259] [Citation(s) in RCA: 91] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Revised: 03/25/2013] [Accepted: 06/01/2013] [Indexed: 11/27/2022]
Abstract
OBJECTIVE Twenty-four-hour urinary free cortisol (UFC) sampling is commonly used to evaluate Cushing's syndrome. Because there are few data on UFC variability in patients with active Cushing's disease, we analysed baseline UFC in a large patient cohort with moderate-to-severe Cushing's disease and assessed whether variability correlates with hypercortisolism severity. These data will help clinicians establish the minimum number of UFC samples required to obtain reliable data. DESIGN Observational study (enrolment phase of Phase III study). METHODS Patients (n = 152) with persistent/recurrent or de novo Cushing's disease and mean UFC (mUFC) ≥1·5×ULN (normal: 30-145 nmol/24 h) were included. Mean UFC level was calculated from four 24-h urine samples collected over 2 weeks. RESULTS Over 600 24-h UFC samples were analysed. The mUFC levels of samples 1 and 2 and samples 3 and 4 were 1000 nmol/24 h (SD 1872) and 940 nmol/24 h (SD 2148), respectively; intrapatient coefficient of variation (CV) was 38% for mUFC. The intrapatient CV using all four samples was 52% (95% CI: 48-56). The intrapatient CV was 51% (95% CI: 44-58) for samples 1 and 2, 49% (95% CI: 43-56) for samples 3 and 4 and 54% (95% CI: 49-59) for samples 1, 2 and 3. Variability in mUFC increased as UFC levels increased. There were no correlations between UFC and clinical features of hypercortisolism. CONCLUSIONS There is intrapatient variability of approximately 50% in 24-h UFC measurements, which is relevant to targets set to estimate any treatment effect. Analysing more than two 24-h collection periods in individual patients does not result in a relevant decrease in variability. Interestingly, UFC levels did not correlate with hypercortisolism severity.
Collapse
Affiliation(s)
- S Petersenn
- ENDOC Center for Endocrine TumorsHamburg, Germany
| | - J Newell-Price
- The Medical School, University of SheffieldSheffield, UK
| | - J W Findling
- Division of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of WisconsinMilwaukee, WI, USA
| | - F Gu
- Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College HospitalBeijing, China
| | - M Maldonado
- Clinical Development, Oncology Business Unit, Novartis Pharma AGBasel, Switzerland
| | - K Sen
- Oncology Biometrics and Data Management, Novartis Pharmaceuticals CorporationFlorham Park, NJ, USA
| | - L R Salgado
- General Internal Medicine Service, Hospital das Clínicas, University of São Paulo Medical SchoolSão Paulo, Brazil
| | - A Colao
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli ‘Federico II’Naples, Italy
| | - B M K Biller
- Neuroendocrine Clinical Center, Massachusetts General HospitalBoston, MA, USA
- Correspondence: Stephan Petersenn, ENDOC Center for Endocrine Tumors, Altonaer Str. 59, 20357 Hamburg, Germany. Tel.: +49 40 401 87985; Fax: +49 40 401 86629; E-mail:
| |
Collapse
|
22
|
Schiff M, Fleischmann R, Weinblatt M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M. OP0022 Abatacept sc versus adalimumab on background methotrexate in RA: One year results from the ample study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.1705] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
|
24
|
Fleischmann R, Weinblatt M, Schiff M, Khanna D, Rosenblatt L, Maldonado M, Furst D. SAT0129 Improved Quality of Life, Work Productivity, General Activity and Independence in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results from the Ample Trial. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Schiff M, Alten R, Weinblatt M, Nash P, Fleischmann R, Durez P, Kaine J, Delaet I, Kelly S, Maldonado M, Patel S, Genovese M. AB0323 Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
Fleischmann R, Schiff M, Weinblatt M, Maldonado M, Massarotti E, Yazici Y. SAT0132 Remission, Low Disease Activity, and Associated Changes in Physical Function and Radiographic Outcomes with Subcutaneous Abatacept or Adalimumab: Results from the Ample Trial. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Schiff M, Weinblatt M, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R. OP0044 Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Two Year Results from the Ample Study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.249] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
Schiff M, Dougados M, Fleischmann R, Fay J, Maldonado M. FRI0257 Abatacept and anti-tnf monoclonal antibodies: efficacy and safety comparisons. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Mehta P, Holder S, Fisher B, Vincent T, Nadesalingam K, Maciver H, Shingler W, Bakshi J, Hassan S, D'Cruz D, Chan A, Litwic AE, McCrae F, Seth R, McCrae F, Nandagudi A, Jury E, Isenberg D, Karjigi U, Paul A, Rees F, O'Dowd E, Kinnear W, Johnson S, Lanyon P, Bakshi J, Stevens R, Narayan N, Marguerie C, Robinson H, Ffolkes L, Worsnop F, Ostlere L, Kiely P, Dharmapalaiah C, Hassan N, Nandagudi A, Bharadwaj A, Skibinska M, Gendi N, Davies EJ, Akil M, Kilding R, Ramachandran Nair J, Walsh M, Farrar W, Thompson RN, Borukhson L, McFadyen C, Singh D, Rajagopal V, Chan AML, Wearn Koh L, Christie JD, Croot L, Gayed M, Disney B, Singhal S, Grindulis K, Reynolds TD, Conway K, Williams D, Quin J, Dean G, Churchill D, Walker-Bone KE, Goff I, Reynolds G, Grove M, Patel P, Lazarus MN, Roncaroli F, Gabriel C, Kinderlerer AR, Nikiphorou E, Hall FC, Bruce E, Gray L, Krutikov M, Wig S, Bruce I, D'Agostino MA, Wakefield R, Berner Hammer H, Vittecoq O, Galeazzi M, Balint P, Filippucci E, Moller I, Iagnocco A, Naredo E, Ostergaard M, Gaillez C, Kerselaers W, Van Holder K, Le Bars M, Stone MA, Williams F, Wolber L, Karppinen J, Maatta J, Thompson B, Atchia I, Lorenzi A, Raftery G, Platt P, Platt PN, Pratt A, Turmezei TD, Treece GM, Gee AH, Poole KE, Chandratre PN, Roddy E, Clarson L, Richardson J, Hider S, Mallen C, Lieberman A, Prouse PJ, Mahendran P, Samarawickrama A, Churchill D, Walker-Bone KE, Ottery FD, Yood R, Wolfson M, Ang A, Riches P, Thomson J, Nuki G, Humphreys J, Verstappen SM, Chipping J, Hyrich K, Marshall T, Symmons DP, Roy M, Kirwan JR, Marshall RW, Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Scott DL, Steer S, Ma MH, Dahanayake C, Scott IC, Kingsley G, Cope A, Scott DL, Dahanayake C, Ma MH, Scott IC, Kingsley GH, Cope A, Scott DL, Wernham A, Ward L, Carruthers D, Deeming A, Buckley C, Raza K, De Pablo P, Nikiphorou E, Carpenter L, Jayakumar K, Solymossy C, Dixey J, Young A, Singh A, Penn H, Ellerby N, Mattey DL, Packham J, Dawes P, Hider SL, Ng N, Humby F, Bombardieri M, Kelly S, Di Cicco M, Dadoun S, Hands R, Rocher V, Kidd B, Pyne D, Pitzalis C, Poore S, Hutchinson D, Low A, Lunt M, Mercer L, Galloway J, Davies R, Watson K, Dixon W, Symmons D, Hyrich K, Mercer L, Lunt M, Low A, Galloway J, Watson KD, Dixon WG, Symmons D, Hyrich KL, Low A, Lunt M, Mercer L, Bruce E, Dixon W, Hyrich K, Symmons D, Malik SP, Kelly C, Hamilton J, Heycock C, Saravanan V, Rynne M, Harris HE, Tweedie F, Skaparis Y, White M, Scott N, Samson K, Mercieca C, Clarke S, Warner AJ, Humphreys J, Lunt M, Marshall T, Symmons D, Verstappen S, Chan E, Kelly C, Woodhead FA, Nisar M, Arthanari S, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A, Kelly C, Chan E, Ahmad Y, Woodhead FA, Nisar M, Arthanari S, Dawson J, Sathi N, Koduri G, Young A, Cumming J, Stannett P, Hull R, Metsios G, Stavropoulos Kalinoglou A, Veldhuijzen van Zanten JJ, Nightingale P, Koutedakis Y, Kitas GD, Nikiphorou E, Dixey J, Williams P, Kiely P, Walsh D, Carpenter L, Young A, Perry E, Kelly C, de-Soyza A, Moullaali T, Eggleton P, Hutchinson D, Veldhuijzen van Zanten JJ, Metsios G, Stavropoulos-Kalinoglou A, Sandoo A, Kitas GD, de Pablo P, Maggs F, Carruthers D, Faizal A, Pugh M, Jobanputra P, Kehoe O, Cartwright A, Askari A, El Haj A, Middleton J, Aynsley S, Hardy J, Veale D, Fearon U, Wilson G, Muthana M, Fossati G, Healy L, Nesbitt A, Becerra E, Leandro MJ, De La Torre I, Cambridge G, Nelson PN, Roden D, Shaw M, Davari Ejtehadi H, Nevill A, Freimanis G, Hooley P, Bowman S, Alavi A, Axford J, Veitch AM, Tugnet N, Rylance PB, Hawtree S, Muthana M, Aynsley S, Mark Wilkinson J, Wilson AG, Woon Kam N, Filter A, Buckley C, Pitzalis C, Bombardieri M, Croft AP, Naylor A, Zimmermann B, Hardie D, Desanti G, Jaurez M, Muller-Ladner U, Filer A, Neumann E, Buckley C, Movahedi M, Lunt M, Ray DW, Dixon WG, Burmester GR, Matucci-Cerinic M, Navarro-Blasco F, Kary S, Unnebrink K, Kupper H, Mukherjee S, Cornell P, Richards S, Rahmeh F, Thompson PW, Westlake SL, Javaid MK, Batra R, Chana J, Round G, Judge A, Taylor P, Patel S, Cooper C, Ravindran V, Bingham CO, Weinblatt ME, Mendelsohn A, Kim L, Mack M, Lu J, Baker D, Westhovens R, Hewitt J, Han C, Keystone EC, Fleischmann R, Smolen J, Emery P, Genovese M, Doyle M, Hsia EC, Hart JC, Lazarus MN, Kinderlerer AR, Harland D, Gibbons C, Pang H, Huertas C, Diamantopoulos A, Dejonckheere F, Clowse M, Wolf D, Stach C, Kosutic G, Williams S, Terpstra I, Mahadevan U, Smolen J, Emery P, Ferraccioli G, Samborski W, Berenbaum F, Davies O, Koetse W, Bennett B, Burkhardt H, Weinblatt ME, Fleischmann R, Davies O, Luijtens K, van der Heijde D, Mariette X, van Vollenhoven RF, Bykerk V, de Longueville M, Arendt C, Luijtens K, Cush J, Khan A, Maclaren Z, Dubash S, Chalam VC, Sheeran T, Price T, Baskar S, Mulherin D, Molloy C, Keay F, Heritage C, Douglas B, Fleischmann R, Weinblatt ME, Schiff MH, Khanna D, Furst DE, Maldonado MA, Li W, Sasso EH, Emerling D, Cavet G, Ford K, Mackenzie-Green B, Collins D, Price E, Williamson L, Golla J, Vagadia V, Morrison E, Tierney A, Wilson H, Hunter J, Ma MH, Scott DL, Reddy V, Moore S, Ehrenstein M, Benson C, Wray M, Cairns A, Wright G, Pendleton A, McHenry M, Taggart A, Bell A, Bosworth A, Cox M, Johnston G, Shah P, O'Brien A, Jones P, Sargeant I, Bukhari M, Nusslein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen W, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M, Lempp H, Hofmann D, Adu A, Congreve C, Dobson J, Rose D, Simpson C, Wykes T, Cope A, Scott DL, Ibrahim F, Schiff M, Alten R, Weinblatt ME, Nash P, Fleischmann R, Durez P, Kaine J, Delaet I, Kelly S, Maldonado M, Patel S, Genovese M, Jones G, Sebba A, Lepley D, Devenport J, Bernasconi C, Smart D, Mpofu C, Gomez-Reino JJ, Verma I, Kaur J, Syngle A, Krishan P, Vohra K, Kaur L, Garg N, Chhabara M, Gibson K, Woodburn J, Telfer S, Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP, Genovese M, Sebba A, Rubbert-Roth A, Scali JJ, Alten R, Kremer JM, Pitts L, Vernon E, van Vollenhoven RF, Sharif MI, Das S, Emery P, Maciver H, Shingler W, Helliwell P, Sokoll K, Vital EM. Case Reports * 1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGF Receptor Mutations in Benign Joint Hypermobility. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Wörheide G, Dohrmann M, Erpenbeck D, Larroux C, Maldonado M, Voigt O, Borchiellini C, Lavrov DV. Deep phylogeny and evolution of sponges (phylum Porifera). Adv Mar Biol 2012; 61:1-78. [PMID: 22560777 DOI: 10.1016/b978-0-12-387787-1.00007-6] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Sponges (phylum Porifera) are a diverse taxon of benthic aquatic animals of great ecological, commercial, and biopharmaceutical importance. They are arguably the earliest-branching metazoan taxon, and therefore, they have great significance in the reconstruction of early metazoan evolution. Yet, the phylogeny and systematics of sponges are to some extent still unresolved, and there is an on-going debate about the exact branching pattern of their main clades and their relationships to the other non-bilaterian animals. Here, we review the current state of the deep phylogeny of sponges. Several studies have suggested that sponges are paraphyletic. However, based on recent phylogenomic analyses, we suggest that the phylum Porifera could well be monophyletic, in accordance with cladistic analyses based on morphology. This finding has many implications for the evolutionary interpretation of early animal traits and sponge development. We further review the contribution that mitochondrial genes and genomes have made to sponge phylogenetics and explore the current state of the molecular phylogenies of the four main sponge lineages (Classes), that is, Demospongiae, Hexactinellida, Calcarea, and Homoscleromorpha, in detail. While classical systematic systems are largely congruent with molecular phylogenies in the class Hexactinellida and in certain parts of Demospongiae and Homoscleromorpha, the high degree of incongruence in the class Calcarea still represents a challenge. We highlight future areas of research to fill existing gaps in our knowledge. By reviewing sponge development in an evolutionary and phylogenetic context, we support previous suggestions that sponge larvae share traits and complexity with eumetazoans and that the simple sedentary adult lifestyle of sponges probably reflects some degree of secondary simplification. In summary, while deep sponge phylogenetics has made many advances in the past years, considerable efforts are still required to achieve a comprehensive understanding of the relationships among and within the main sponge lineages to fully appreciate the evolution of this extraordinary metazoan phylum.
Collapse
Affiliation(s)
- G Wörheide
- Department of Earth and Environmental Sciences, Ludwig-Maximilians-Universität München, München, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Rives S, Estella J, Gómez P, López-Duarte M, de Miguel PG, Verdeguer A, Moreno MJ, Vivanco JL, Couselo JM, Fernández-Delgado R, Maldonado M, Tasso M, López-Ibor B, Lendínez F, López-Almaraz R, Uriz J, Melo M, Fernández-Teijeiro A, Rodríguez I, Badell I. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011; 154:600-11. [PMID: 21707583 DOI: 10.1111/j.1365-2141.2011.08783.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Philadelphia-chromosome acute lymphoblastic leukaemia (Ph+ ALL) is a subgroup of ALL with very high risk of treatment failure. We report here the results of the Sociedad Española de Hematología y Oncología Pediátricas (SEHOP/SHOP) in paediatric Ph+ ALL treated with intermediate-dose imatinib concurrent with intensive chemotherapy. The toxicities and outcome of these patients were compared with historical controls not receiving imatinib. Patients with Ph+ ALL aged 1-18years were enrolled in three consecutive ALL/SHOP trials (SHOP-94/SHOP-99/SHOP-2005). In the SHOP-2005 trial, imatinib (260mg/m(2) per day) was given on day-15 of induction. Allogeneic haematopoietic stem-cell transplantation (HSCT) from a matched related or unrelated donor was scheduled in first complete remission (CR1). Forty-three patients were evaluable (22 boys, median age 6·8years, range, 1·2-15). Sixteen received imatinib whereas 27 received similar chemotherapy without imatinib. Seventeen of 27 and 15 of 16 patients in the non-imatinib and imatinib cohort, respectively, underwent HSCT in CR1. With a median follow-up of 109 and 39months for the non-imatinib and imatinib cohorts, the 3-year event-free survival (EFS) was 29·6% and 78·7%, respectively (P=0·01). These results show that, compared to historical controls, intermediate dose of imatinib given concomitantly with chemotherapy and followed by allogeneic HSCT markedly improved early EFS in paediatric Ph+ ALL.
Collapse
Affiliation(s)
- Susana Rives
- Paediatric Haematology Department, Hospital Sant Joan de Déu de Barcelona Universitat de Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
De la Riva I, Maldonado M. First record of Leptodactylus ocellatus (Linnaeus, 1758) (Amphibia, Anura, Leptodactylidae) in Bolivia and comments on related species. GRAELLSIA 2011. [DOI: 10.3989/graellsia.1999.v55.i0.328] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
33
|
Ebbens FA, Maldonado M, de Groot EJJ, Alobid I, van Drunen CM, Picado C, Fokkens WJ, Mullol J. Topical glucocorticoids downregulate COX-1 positive cells in nasal polyps. Allergy 2009; 64:96-103. [PMID: 19132974 DOI: 10.1111/j.1398-9995.2008.01815.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Influx of inflammatory cells is one of the hallmarks of nasal polyposis. As glucocorticoids (GC) are known to exhibit strong anti-inflammatory effects, these drugs are frequently used in the treatment of the disease. Part of the anti-inflammatory effects of GC is attributed to their interference with prostanoid synthesis. As cyclooxygenases (COX) are key enzymes in the synthesis of both pro- (COX-1, COX-2) and anti-inflammatory prostanoids (COX-2), we investigated the role of topical GC on COX-1, COX-2 and inflammatory markers in nasal polyps (NP). METHODS Immunohistochemical analysis of inflammatory markers (CD68, CD117, MBP, elastase, IgE, BB-1, IL-4, IL-5 and IL-6), COX-1 and COX-2 was performed on normal nasal mucosa (NM) (n = 18), non-GC treated NP (n = 27) and topical GC treated NP (n = 12). NP groups were matched for allergy, asthma and ASA intolerance. RESULTS Increased numbers of eosinophils, IL-5+ cells and IgE+ cells and decreased numbers of mastcells are striking features of NP inflammation (P < 0.05). In addition, increased numbers of COX-1+ cells are observed in NP epithelium compared to NM (P < 0.05). CONCLUSION Topical GC significantly reduce the number of COX-1+ NP cells (P < 0.05), but have no significant effect on COX-2+ NP cells. No significant reduction in the number of eosinophils is observed for GC treated NP. The number of IL-5+ cells is however increased significantly upon GC treatment (P < 0.05).
Collapse
Affiliation(s)
- F A Ebbens
- Department of Otorhinolaryngology Head & Neck Surgery, Academic Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Riesgo A, Maldonado M, Durfort M. Occurrence of somatic cells within the spermatic cysts of demosponges: a discussion of their role. Tissue Cell 2008; 40:387-96. [PMID: 18501394 DOI: 10.1016/j.tice.2008.03.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2008] [Accepted: 03/31/2008] [Indexed: 11/28/2022]
Abstract
During ultrastructural studies on the spermatogenesis of two demosponges, Raspaciona aculeata and Petrosia ficiformis, somatic cells were detected within their spermatic cysts. In R. aculeata large, amoeboid somatic cells, presumably derived from follicle cells, were found inside cysts filled with secondary spermatocytes. These cells were actively phagocytosing spermatocytes. Such phagocytosis could be directed to eliminate aberrant spermatogenic cells, maintain appropriate cell number within the cysts, or recapture energetic reserves originally allocated to the reproductive process via phagocytosis of spermatocytes. In P. ficiformis, somatic round cells were observed only after the spawning event, phagocytosing unspawned sperm in nearly emptied spermatic cysts. Unlike in R. aculeata, these cells were more similar to archaeocytes (common cells of the demosponge mesohyl with phagocytic activity) than to follicle cells. Phagocytosis of spermatogenic cells and unspawned spermatozoa by somatic cells from the wall of the testes is a well-known process in vertebrates and many invertebrates. Occurrence of somatic cells in the spermatic cysts of sponges, whose function appears to be partially analogous to that of Sertoli cells, reveals that sponges possess cellular mechanisms to regulate testis functioning that are equivalent to those in higher metazoans.
Collapse
Affiliation(s)
- A Riesgo
- Department of Marine Ecology, Centro de Estudios Avanzados de Blanes (CSIC), Acceso Cala St. Francesc 14, Blanes 17300, Girona, Spain.
| | | | | |
Collapse
|
35
|
Alvarenga N, Canela N, Gómez R, Yaluff G, Maldonado M. Leishmanicidal activity of Maytenus illicifolia roots. Fitoterapia 2008; 79:381-3. [PMID: 18504075 DOI: 10.1016/j.fitote.2008.03.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2007] [Accepted: 03/06/2008] [Indexed: 12/01/2022]
Abstract
In vitro evaluation of leishmanicidal activity of aqueous and ethanolic extracts of Maytenus illicifolia against three species of Leishmania. The root extracts showed differential activity against parasites, whereas the aerial part of the extracts was inactive.
Collapse
Affiliation(s)
- Nelson Alvarenga
- Departamento de Fitoquímica, Facultad de Ciencias Químicas, Universidad Nacional de Asunción, PO BOX 1055, San Lorenzo, Paraguay.
| | | | | | | | | |
Collapse
|
36
|
Hojman M, Murano F, Manonelles G, Maldonado M, Ahmed N, Vera MS, Prieto M. HIV maternal-fetal transmission in a low resources setting in the outskirts of Buenos Aires, Argentina. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
37
|
Valero N, Larreal Y, Espina LM, Reyes I, Maldonado M, Mosquera J. Elevated levels of interleukin-2 receptor and intercellular adhesion molecule 1 in sera from a venezuelan cohort of patients with dengue. Arch Virol 2007; 153:199-203. [PMID: 18080798 DOI: 10.1007/s00705-007-1080-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2007] [Accepted: 09/16/2007] [Indexed: 10/22/2022]
Abstract
This study evaluated the levels of soluble interleukin-2 receptor (sIL-2R) and soluble intercellular adhesion molecule-1 (sICAM-1) in patients with dengue. Sera from 17 patients with dengue fever (DF), 15 with dengue hemorrhagic fever (DHF) and 12 healthy individuals were obtained. Increased levels of sIL-2R and sICAM-1 were found in patients with DF and DHF when compared to normal; those were not correlated with leukocytes, hepatic serum enzyme levels or haemostatic parameters. Levels of sIL-2R were related to the different grades of DHF. These results suggest that increased levels of sIL-2R and sICAM-1 are a common feature of dengue.
Collapse
Affiliation(s)
- N Valero
- Seccion de Virologia, Facultad de Medicina, Instituto de Investigaciones Clinicas Dr. Americo Negrette, Universidad del Zulia, Zulia, Venezuela.
| | | | | | | | | | | |
Collapse
|
38
|
Quintanar-Escorza MA, González-Martínez MT, Navarro L, Maldonado M, Arévalo B, Calderón-Salinas JV. Intracellular free calcium concentration and calcium transport in human erythrocytes of lead-exposed workers. Toxicol Appl Pharmacol 2007; 220:1-8. [PMID: 17292428 DOI: 10.1016/j.taap.2006.10.016] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2006] [Revised: 10/11/2006] [Accepted: 10/19/2006] [Indexed: 01/29/2023]
Abstract
Erythrocytes are the route of lead distribution to organs and tissues. The effect of lead on calcium homeostasis in human erythrocytes and other excitable cells is not known. In the present work we studied the effect of lead intoxication on the uptake and efflux (measured as (Ca(2+)-Mg(2+))-ATPase activity) of calcium were studied in erythrocytes obtained from lead-exposed workers. Blood samples were taken from 15 workers exposed to lead (blood lead concentration 74.4+/-21.9 microg/dl) and 15 non-exposed workers (9.9+/-2 microg/dl). In erythrocytes of lead-exposed workers, the intracellular free calcium was 79+/-13 nM, a significantly higher concentration (ANOVA, P<0.01) than the one detected in control (30+/-9 nM). The enhanced intracellular free calcium was associated with a higher osmotic fragility and with important modifications in erythrocytes shape. The high intracellular free calcium in lead-exposed workers was also related to a 100% increase in calcium incorporation and to 50% reduction of (Ca(2+)-Mg(2+))-ATPase activity. Lipid peroxidation was 1.7-fold higher in erythrocytes of lead-exposed workers as compared with control. The alteration on calcium equilibrium in erythrocytes is discussed in light of the toxicological effects in lead-exposed workers.
Collapse
Affiliation(s)
- M A Quintanar-Escorza
- Department of Biochemistry, CINVESTAV-IPN, P.O. Box 14-740, Mexico City 07000, Mexico
| | | | | | | | | | | |
Collapse
|
39
|
Maldonado M, Kebriaei P, Granada M, Szewczyk N. 392: Fundamental nursing responsibilities in mesenchymal stem cell infusion. Biol Blood Marrow Transplant 2007. [DOI: 10.1016/j.bbmt.2007.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
40
|
Sánchez LV, Tanaka Y, Maldonado M, Mizokami M, Panduro A. Difference of hepatitis B virus genotype distribution in two groups of mexican patients with different risk factors. High prevalence of genotype H and G. Intervirology 2006; 50:9-15. [PMID: 17164552 DOI: 10.1159/000096307] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2005] [Accepted: 10/26/2005] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hepatitis B virus (HBV) has been classified in eight genotypes, from A to H (HBV/A to HBV/H). HBV genotypes were determined in two groups with different risk factors. METHODS Group I consisted of 42 patients with chronic and acute hepatitis and group II with 25 men who have sex with men (MSM). HBV genotypes were determined by DNA sequencing of the S-gene. RESULTS Both groups differed with respect to genotype distribution (p < 0.001). In group I, there were 31 (74%), 9 (21%) and 2 patients (5%) with HBV/H, HBV/D and HBV/A; respectively. In group II, HBV/H, HBV/A, and HBV/G were found in 13 (52%), 8 (32%) and 4 (16%) cases, respectively. By using an HBV/G-specific PCR, 3 more cases of HBV/G were identified in group II, rising to a total 28%. All HBV/G strains were present in coinfection with other HBV genotypes, 86% with HBV/H, and 14% with HBV/A. CONCLUSIONS HBV/H predominated in both groups. A high frequency of HBV/G was found in MSM, which was always coinfected with HBV/H or HBV/A. Significant differences in HBV genotype distribution were also found, since HBV/D was present only in patients with liver disease, whereas HBV/G was present only in MSM.
Collapse
Affiliation(s)
- L V Sánchez
- Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, Health Sciences Center, University of Guadalajara, Guadalajara, Mexico
| | | | | | | | | |
Collapse
|
41
|
Maldonado M, Alobid I, Bernal-Sprekelsen M, Mullol J. [Sphenochoanal polyp. Diagnostic and therapeutic aspects]. Acta Otorrinolaringol Esp 2006; 57:149-51. [PMID: 16615569 DOI: 10.1016/s0001-6519(06)78681-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION Sphenochoanal polyps (SCP) grow from the sphenoid sinus and occupy the nasopharynx. OBJECTIVE AND RESULTS To describe the clinical and diagnostic features of SCP, reporting two cases. Epidemiological study of the series in the literature. 8 published series were found (22 cases). CONCLUSIONS SCP is a rare lesion that is usually misdiagnosed for antrochoanal polyposis. A proper diagnosis and surgical treatment are the basis to prevent recurrence. We describe the first case of SCP with cacosmia.
Collapse
Affiliation(s)
- M Maldonado
- Unidad de Rinología, Servicio de Otorrinolaringología, Hospital Clínic, Barcelona.
| | | | | | | |
Collapse
|
42
|
Cassol V, Rizzato T, Teche S, Basso D, Hirata V, Maldonado M, Colpo E, Solé D. Prevalence and Severity of Asthma among Adolescents and its Relationship with the Body Mass Index. J Allergy Clin Immunol 2006. [DOI: 10.1016/j.jaci.2005.12.852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
Maldonado M, D'Amico S, Otiniano M, Balasubramanyam A, Rodriguez L, Cuevas E. Predictors of glycaemic control in indigent patients presenting with diabetic ketoacidosis. Diabetes Obes Metab 2005; 7:282-9. [PMID: 15811146 DOI: 10.1111/j.1463-1326.2004.00394.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIM To derive predictors of good glycaemic control in patients presenting with diabetic ketoacidosis (DKA) followed prospectively in a specialized clinic. METHODS One hundred and sixty-one adult patients were admitted during a 31-month period and followed for at least 12 months. After 1 year, the patients were classified into three groups: good control (GC) (HbA1c < or = 7%), intermediate control (IC) (HbA1c 7-9%) and poor control (PC) (HbA1c > 9%). Characteristics of patients in the three groups were compared both at baseline and during follow-up. RESULTS At 12 months, 36% of the patients were classified as GC, 27% as IC and 37% as PC. GC patients had higher fasting serum C-peptide levels 0.7 +/- 0.54 compared to 0.38 +/- 0.29 and 0.16 +/- 0.21 nmol/l, respectively, for the IC and PC patients (p < 0.0001). A higher proportion GC patient had a C-peptide level greater than 0.33 nmol/l than that for IC and PC patients (86, 61 and 19%, respectively; p < 0.0001). Exogenous insulin was safely discontinued in 50, 30 and 3% of patients, respectively, in the GC, IC and PC groups (p < 0.0001). Compliance with life-style interventions was higher in the GC than that in IC and PC patients (87, 41 and 5%, respectively; p < 0.0001). In the logistic regression analysis, predictors of good glycaemic control were having baseline fasting serum C-peptide value > or =0.33 mmol/l, OR: 3.01 (95% CI 1.07-8.55, p = 0.03) and compliance with life-style interventions OR 12.66 (95% CI 3.73-51.57, p = 0.0001). CONCLUSION Among adult patients with DKA, significant predictors of good glycaemic control are preserved beta-cell function and compliance with life-style modifications.
Collapse
Affiliation(s)
- M Maldonado
- Department of Medicine/Endocrinology, Baylor College of Medicine, One Baylor Plaza, Rm. N520, Houston, TX 77030, USA.
| | | | | | | | | | | |
Collapse
|
44
|
|
45
|
Maldonado M, Mullol J, Bernal-Sprekelsen M. [On the translation of lobar and lobectomy into Spanish]. Arch Bronconeumol 2005; 41:295. [PMID: 15919013 DOI: 10.1016/s1579-2129(06)60225-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
|
46
|
Ebbens F, Maldonado M, Groot de E, Alobid I, Drunen van C, Picado C, Fokkens W, Mullol J. Glucocorticoids downregulate COX-1 positive cells in nasal polyps. J Allergy Clin Immunol 2005. [DOI: 10.1016/j.jaci.2004.12.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Rojas de Arias A, Lehane MJ, Schofield CJ, Maldonado M. Pyrethroid insecticide evaluation on different house structures in a Chagas disease endemic area of the Paraguayan Chaco. Mem Inst Oswaldo Cruz 2004; 99:657-62. [PMID: 15558181 DOI: 10.1590/s0074-02762004000600022] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Insecticide effects of deltamethrin 2.5% SC (flowable solution) on different substrates and triatomine infestation rates in two indigenous villages (Estancia Salzar and Nueva Promesa) of the Paraguayan Chaco are reported. This field study was carried out to determine the extent to which variability in spray penetration may affect residual action of the insecticide. A total of 117 houses in the two villages were sprayed. Filter papers discs were placed on aluminium foil pinned to walls and roofs in selected houses and the applied insecticide concentration was determined by high pressure liquid chromatography (HPLC). The target dose rate was 25 mg a.i./m2. The mean actual applied dose in Estancia Salazar was 11.2 +/- 3.1 mg a.i./m2 in walls and 11.9 +/- 5.6 mg a.i./m2 in roofs while in Nueva Promesa, where duplicates were carried out, the mean values were 19.9 +/- 6.9 mg a.i./m2 and 34.7 +/- 10.4 mg a.i./m2 in walls and 28.8 +/- 19.2 mg a.i./m2 and 24.9 +/- 21.8 mg a.i./m2 in roofs. This shows the unevenness and variability of applied doses during spraying campaigns, and also the reduced coverage over roof surfaces. However, wall bioassays with Triatoma infestans nymphs in a 72 h exposure test showed that deposits of deltamethrin persisted in quantities sufficient to kill triatomines until three months post spraying. Knockdown by deltamethrin on both types of surfaces resulted in 100% final mortality. A lower insecticidal effect was observed on mud walls. However, three months after treatment, sprayed lime-coated mud surfaces displayed a twofold greater capacity (57.5%) to kill triatomines than mud sprayed surfaces (25%). Re-infestation was detected by manual capture only in one locality, six months after spraying.
Collapse
Affiliation(s)
- Antonieta Rojas de Arias
- Departamento de Medicina Tropical, Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, Asunción, Paraguay.
| | | | | | | |
Collapse
|
48
|
Verdeguer A, Muñoz A, Cañete A, Pardo N, Martínez A, Donat J, Gómez P, Bureo E, Fernández JM, Cubells J, Maldonado M, Sastre A. Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon). Pediatr Hematol Oncol 2004; 21:495-504. [PMID: 15552813 DOI: 10.1080/08880010490477284] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The authors retrospectively analyzed the long-term outcome of 67 patients over 1 year of age at diagnosis with high-risk neuroblastoma (stage 4 or stage 3 with N-myc amplification) who were treated with megatherapy and stem cell rescue from 1984 to 1998. Median age at transplant was 4 years (range 1.6-15 years). The source of cells was peripheral stem cells in 29 and bone marrow in 38 patients. In 12 patients, an in vitro purging of bone marrow harvest was performed. Most patients were conditioned with melphalan, BCNU, and VM-26. After transplant 19 patients received complementary treatment with IL-2 (16) or 13-cis-retinoic acid (3). Six patients (8%) died from transplant-related toxicity and 39 from disease progression. Three patients were alive with active disease at the time of analysis. Nineteen patients are alive and disease-free at a median follow-up of 104 months. Five-year event-free survival is 0.30. Survival of patients who received a purged graft was not significantly better than the rest. Post-transplant complementary treatment significantly improved overall and event-free survival (p = .01 and p = .04, respectively).
Collapse
|
49
|
Muñoz A, Maldonado M, Pardo N, Fernández JM, Vela E, Cubells J. Pegylated liposomal doxorubicin hydrochloride (PLD) for advanced sarcomas in children: preliminary results. Pediatr Blood Cancer 2004; 43:152-5. [PMID: 15236282 DOI: 10.1002/pbc.20029] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Arturo Muñoz
- Department of Pediatrics, Hospital Ramón y Cajal, Alcalá University, Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
50
|
Abstract
OBJECTIVE To describe a rare case of sarcoidosis diagnosed after surgical resection of an adenoma in a patient with Cushing's disease. METHODS We present a case report and discuss the only other similar case identified from the published medical literature. RESULTS In a 33-year-old woman with symptoms of cortisol excess (including progressive weight gain, proximal muscle weakness, ecchymoses, and amenorrhea), laboratory studies showed serum cortisol values consistent with Cushing's syndrome. After inferior petrosal sinus sampling, the patient underwent surgical resection of an adenoma in the right aspect of the anterior pituitary gland. Maintenance corticosteroid therapy was implemented, and the signs and symptoms of Cushing's disease began to resolve. Five months postoperatively, multiple erythematous lesions developed on the patient's arms and legs. Skin biopsy specimens demonstrated noncaseating granulomas, and sarcoidosis was diagnosed. Two months later, the lesions resolved spontaneously without therapy other than continued corticosteroid replacement. CONCLUSION Physicians should be aware that unusual postoperative symptoms in a patient who has undergone successful treatment of Cushing's syndrome may be attributable to the emergence of another corticosteroid-responsive disease such as sarcoidosis.
Collapse
Affiliation(s)
- M Maldonado
- Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | | | | | | | | | | |
Collapse
|